RegOpsPro™

GDP Control in Practice · Issue 003

EU GDP Reform: Are We Moving Towards More Risk-Based Distribution Controls?

Europe is preparing to revisit GDP. What could a more proportionate approach mean for wholesale distributors and Responsible Persons?

Published by RegOpsPro17 November 20268 minute read
Risk
Evidence
Decision
Action
Effectiveness

Europe is preparing to revisit its Good Distribution Practice framework for the first time since 2013. But the real opportunity may not be more regulation. It may be clearer expectations around how pharmaceutical distributors demonstrate effective, proportionate control.

The European pharmaceutical distribution sector has changed considerably since the current EU GDP guidelines were published in 2013. Supply chains are more complex, outsourced logistics arrangements are increasingly common, digital systems play a greater role in operational control, and medicine shortages have placed additional pressure on distribution networks.

Yet the regulatory framework underpinning much of this activity remains largely unchanged. Recent discussions surrounding the EU pharmaceutical reform indicate that GDP requirements are now being reconsidered, with the intention of moving from the existing guidelines towards a directly applicable delegated regulation.

For wholesale distributors, quality teams and Responsible Persons, this is a development worth following. However, the most interesting question is not simply what the revised legislation will say. It is whether the reform will encourage a more consistent, risk-based approach to demonstrating GDP compliance.

Why is EU GDP being reviewed?

The existing EU GDP guidelines, published as 2013/C 343/01, establish expectations for pharmaceutical distribution, including quality management, personnel, premises, transport, outsourced activities, documentation and self-inspection. These principles remain relevant.

However, differences in interpretation between Member States can create practical difficulties for organisations operating across multiple markets. At the November 2026 PharmaSupply conference, the European Healthcare Distribution Association (GIRP) highlighted the opportunity to create a more harmonised, proportionate and future-proof GDP framework.

The sector is seeking greater consistency without introducing unnecessary operational costs or compromising medicine quality. Importantly, the revised GDP text has not yet been published. The EMA GDP Drafting Group has begun its work, and public consultation is expected. We are therefore discussing the direction of potential reform rather than confirmed new regulatory requirements.

Risk-based GDP: What does proportionate control actually mean?

Risk-based decision-making is already fundamental to effective GDP. The difficulty is often translating that principle into practical, defensible decisions. Consider a common example: transport qualification.

A distributor may operate several transport routes involving different journey durations, climatic conditions, vehicle configurations and product requirements. Applying identical controls to every movement may appear consistent, but it does not necessarily mean the controls are proportionate to the actual risks.

A more meaningful approach considers the product's approved storage conditions and stability characteristics; the duration and environmental exposure of the journey; existing qualification and temperature-monitoring evidence; historical deviations and route performance; and the effectiveness of packaging, vehicle and operational controls.

The resulting control strategy should be justified, documented and periodically reviewed. The objective is not to reduce control. It is to demonstrate that the controls selected are appropriate and effective.

The challenge for Responsible Persons

For Responsible Persons, risk-based GDP is not simply about completing a risk assessment. It requires a clear connection between the identified risk, the evidence considered, the decision taken and the effectiveness of the resulting controls.

Take another example: a third-party logistics provider with recurring temperature-recording deficiencies. The immediate response may involve containment, investigation and corrective action. But the wider GDP question is whether the distributor can demonstrate that the supplier remains under appropriate control.

Has potentially affected stock been identified and assessed? Are the deficiencies isolated or indicative of a wider failure? Does the existing supplier qualification remain valid? What additional oversight or restrictions are necessary? Who has authority to approve continued use of the provider? And how will the organisation demonstrate that corrective actions have actually worked?

These are operational decisions, not simply documentation exercises. A risk-based framework only delivers value when decisions can be traced through to implementation and effectiveness.

Digitalisation and cybersecurity

Another important aspect of the emerging discussion is the recognition that distribution operations increasingly depend on digital systems. Temperature-monitoring platforms, warehouse management systems, electronic quality records and supplier data exchanges are now central to many GDP processes.

These systems introduce opportunities for stronger visibility and control, but also dependencies that must be understood and managed. Cybersecurity, data integrity, system availability and business continuity therefore have direct relevance to distribution quality.

The challenge for future GDP requirements will be to accommodate technological developments without prescribing unnecessary solutions. A technologically neutral approach could allow organisations to select systems appropriate to their scale, complexity and risk profile, provided they can demonstrate that the resulting controls are effective.

What does this mean for UK GDP?

An important distinction is that the proposed EU reform does not automatically change GDP requirements in Great Britain. UK wholesale distributors must continue to comply with applicable UK legislation and MHRA expectations.

Any future alignment or divergence would need to be assessed against the final EU legislation and subsequent UK regulatory developments. Northern Ireland also requires separate consideration under its applicable regulatory arrangements.

For UK Responsible Persons, the immediate priority is therefore not to implement requirements that have yet to be published. It is to monitor the reform while continuing to strengthen existing GDP control systems.

What should organisations be doing now?

There is no justification for launching extensive remediation programmes based on unpublished requirements. However, the emerging direction provides a useful opportunity to review whether existing GDP arrangements genuinely demonstrate effective control.

  1. Quality risk assessments provide a clear rationale for decisions rather than simply recording risk scores.
  2. Supplier and outsourced activity oversight is linked to actual performance and emerging risk.
  3. Transport controls are supported by appropriate qualification, monitoring and review.
  4. Digital systems and operational dependencies are reflected in quality risk management.
  5. Deviations, CAPA and management review demonstrate that identified weaknesses are addressed and improvements remain effective.

These are already relevant considerations under the existing GDP framework. The potential reform reinforces their importance rather than creating an immediate new obligation.

From documented compliance to demonstrable control

The revision of EU GDP presents an opportunity to reconsider how distribution quality is demonstrated across increasingly complex supply chains. A more harmonised and proportionate framework could be beneficial, provided the final requirements remain focused on patient safety and effective operational control.

For Responsible Persons and quality leaders, the underlying principle should remain familiar. A compliant system must do more than describe its controls. It must demonstrate that those controls work.

That means connecting requirements, operational evidence, documented decisions, corrective actions and effectiveness reviews. Regardless of how the final EU GDP regulation develops, this remains a practical foundation for inspection readiness and sustainable GDP compliance.

About RegOpsPro

RegOpsPro supports pharmaceutical distribution professionals with practical GDP operating models, structured assessments, regulatory intelligence and Professional workspaces designed to connect evidence, decisions, actions and follow-up. Explore the platform at regopspro.com.

References

  1. EU Perspectives, 11 November 2026: Wholesalers pin their hopes on Europe's medicine reform.
  2. European Commission (2013). Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01).
  3. European Commission. Directive 2001/83/EC, as amended.

Regulatory status: 17 November 2026. This article discusses emerging EU regulatory developments and does not represent confirmation of future GDP requirements.